Physician profile
Mark W Johnson
NPI 1679571715
$12,617.47
in general payments reported to CMS, 2019-2025
42 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $7,356 · 2021: $1,237 · 2022: $1,026 · 2023: $911 · 2024: $1,023 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,395.58 | 2019-2020 | |
| Pfizer INC. | $673.44 | 2019-2025 | |
| Lilly USA, LLC | $546.71 | 2020-2024 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $536.81 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $528.40 | 2019-2025 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $479.69 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.36 | 2019-2025 | Jardiance |
| Abbvie INC. | $393.23 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $391.51 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $355.89 | 2021-2025 | |
| Glaxosmithkline, LLC. | $330.62 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $134.96 | 2020-2021 | |
| Heartflow, INC. | $131.94 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $130.20 | 2022 | |
| Xeris Pharmaceuticals, INC. | $101.06 | 2021-2023 | Gvoke Hypopen |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.